Skip to main content
Top
Published in: Supportive Care in Cancer 3/2019

Open Access 01-03-2019 | Original Article

Risk factors and prediction model for persistent breast-cancer-related lymphedema: a 5-year cohort study

Authors: I-Wen Penn, Yue-Cune Chang, Eric Chuang, Chi-Ming Chen, Chi-Feng Chung, Chia-Yu Kuo, Tien-Yow Chuang

Published in: Supportive Care in Cancer | Issue 3/2019

Login to get access

Abstract

Purpose

Breast-cancer-related lymphedema (BCRL) can be a transient or persistent condition. The aims of this study were to (1) identify and weigh the risk factors for persistent lymphedema (PLE) among all patients with BCRL and (2) establish a prediction model for the occurrence of PLE.

Methods

A cohort of 342 patients with BCRL with a median follow-up of 5 years after the onset of swelling was analyzed. PLE was defined as a hardening of the subcutaneous tissue, the persistence of the circumferential difference (CD) between arms, or a flare-up of swelling during follow-up. Multiple logistic regression was used to identify risk factors for PLE, including tumors, treatments, and patient-related factors. The prediction accuracy of the model was assessed using the area under the receiver operating characteristic curve (AUC).

Results

Of the 342 patients with BCRL, 229 (67%) had PLE. Multiple logistic regression analysis revealed that the number of lymph node metastases (p = 0.012), the maximal CD between arms at the first occurrence of swelling (p < 0.001), and the largest difference during follow-up (p < 0.001) were significant predictors for PLE. The corresponding AUC was 0.908. Although inclusion of body weight gains (p = 0.008) and maximal CD at the latest follow-up (p = 0.002) increased the analytical accuracy (AUC = 0.920), the resulting AUC values (p = 0.113) were not significantly different.

Conclusions

BCRL is persistent in two thirds of patients. Patients with more lymph node metastases, weight gain, and larger CD since the onset of swelling and during follow-up have an increased likelihood of developing PLE.
Literature
1.
go back to reference Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR (2008) Lymphedema and quality of life in breast Cancer survivors: the Iowa Women’s Health Study. J Clin Oncol 26(35):5689–5696CrossRef Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR (2008) Lymphedema and quality of life in breast Cancer survivors: the Iowa Women’s Health Study. J Clin Oncol 26(35):5689–5696CrossRef
2.
go back to reference Velanovich V, Szymanski W (1999) Quality of life of breast cancer patients with lymphedema. Am J Surg 177(3):184–188CrossRef Velanovich V, Szymanski W (1999) Quality of life of breast cancer patients with lymphedema. Am J Surg 177(3):184–188CrossRef
3.
go back to reference Kilbreath SL, Lee M-J, Refshauge KM, Beith JM, Ward LC, Simpson J, Black D (2013) Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer 21(8):2207–2215CrossRef Kilbreath SL, Lee M-J, Refshauge KM, Beith JM, Ward LC, Simpson J, Black D (2013) Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer 21(8):2207–2215CrossRef
4.
go back to reference Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, DeMichele A, Solin LJ (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397CrossRef Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, DeMichele A, Solin LJ (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397CrossRef
5.
go back to reference Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH (2012) Upper-body morbidity after breast cancer. Cancer 118(S8):2237–2249CrossRef Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH (2012) Upper-body morbidity after breast cancer. Cancer 118(S8):2237–2249CrossRef
6.
go back to reference Kim M, Shin KH, Jung S-Y, Lee S, Kang H-S, Lee ES, Chung SH, Kim Y-J, Kim TH, Cho KH (2016) Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat 48(4):1330–1337CrossRef Kim M, Shin KH, Jung S-Y, Lee S, Kang H-S, Lee ES, Chung SH, Kim Y-J, Kim TH, Cho KH (2016) Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat 48(4):1330–1337CrossRef
7.
go back to reference Ad VB, Cheville A, Solin LJ, Dutta P, Both S, Harris EE (2010) Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys 76(1):85–90CrossRef Ad VB, Cheville A, Solin LJ, Dutta P, Both S, Harris EE (2010) Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys 76(1):85–90CrossRef
8.
go back to reference Shah C, Arthur DW, Wazer D, Khan A, Ridner S, Vicini F (2016) The impact of early detection and intervention of breast cancer- related lymphedema: a systematic review. Cancer Med 5(6):1154–1162CrossRef Shah C, Arthur DW, Wazer D, Khan A, Ridner S, Vicini F (2016) The impact of early detection and intervention of breast cancer- related lymphedema: a systematic review. Cancer Med 5(6):1154–1162CrossRef
9.
go back to reference Pereira ACPR, Koifman RJ, Anke Bergmann A (2017) Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 36:67–73CrossRef Pereira ACPR, Koifman RJ, Anke Bergmann A (2017) Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 36:67–73CrossRef
10.
go back to reference Soyder A, Taştaban E, Özbaş S, Boylu S, Özgün H (2014) Frequency of early-stage lymphedema and risk factors in postoperative patients with breast Cancer. J Breast Health 10(2):92–97CrossRef Soyder A, Taştaban E, Özbaş S, Boylu S, Özgün H (2014) Frequency of early-stage lymphedema and risk factors in postoperative patients with breast Cancer. J Breast Health 10(2):92–97CrossRef
11.
go back to reference DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515CrossRef DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515CrossRef
12.
go back to reference McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219CrossRef McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219CrossRef
13.
go back to reference Czerniec S, Ward L, Refshauge K, Beith J, Lee M, York S, Kilbreath S (2010) Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Investig 28(1):54–62CrossRef Czerniec S, Ward L, Refshauge K, Beith J, Lee M, York S, Kilbreath S (2010) Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Investig 28(1):54–62CrossRef
14.
go back to reference Shaitelman SF, Chiang YJ, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN (2017) Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):201–215CrossRef Shaitelman SF, Chiang YJ, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN (2017) Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):201–215CrossRef
15.
go back to reference Kilbreath S, Refshauge K, Beith J, Ward L, Ung O, Dylke E, French J, Yee J, Koelmeyer L, Gaitatzis K (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29–36CrossRef Kilbreath S, Refshauge K, Beith J, Ward L, Ung O, Dylke E, French J, Yee J, Koelmeyer L, Gaitatzis K (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29–36CrossRef
16.
go back to reference Cariati M, Bains SK, Grootendorst MR, Suyo A, Peters AM, Mortimer P, Ellis P, Harries M, Van Hemelrijck M, Purushotham AD (2015) Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg 102(9):1071–1078CrossRef Cariati M, Bains SK, Grootendorst MR, Suyo A, Peters AM, Mortimer P, Ellis P, Harries M, Van Hemelrijck M, Purushotham AD (2015) Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg 102(9):1071–1078CrossRef
17.
go back to reference Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR (2006) Breast cancer-related lymphedema—what are the significant predictors and how they affect the severity of lymphedema? Breast Journal 12(6):536–543CrossRef Soran A, D'Angelo G, Begovic M, Ardic F, Harlak A, Samuel Wieand H, Vogel VG, Johnson RR (2006) Breast cancer-related lymphedema—what are the significant predictors and how they affect the severity of lymphedema? Breast Journal 12(6):536–543CrossRef
18.
go back to reference Yoo J-N, Cheong Y-S, Min Y-S, Lee S-W, Park HY, Jung T-D (2015) Validity of quantitative lymphoscintigraphy as a lymphedema assessment tool for patients with breast cancer. Ann Rehabil Med 39(6):931–940CrossRef Yoo J-N, Cheong Y-S, Min Y-S, Lee S-W, Park HY, Jung T-D (2015) Validity of quantitative lymphoscintigraphy as a lymphedema assessment tool for patients with breast cancer. Ann Rehabil Med 39(6):931–940CrossRef
19.
go back to reference Földi M, Földi E, Strößenreuther R, Kubik S (2012) Földi's textbook of lymphology: for physicians and lymphedema therapists. Elsevier Health Sciences Földi M, Földi E, Strößenreuther R, Kubik S (2012) Földi's textbook of lymphology: for physicians and lymphedema therapists. Elsevier Health Sciences
20.
go back to reference Joachim EZ, Norton S (2009) Lymphedema management: the comprehensive guide for practitioners Joachim EZ, Norton S (2009) Lymphedema management: the comprehensive guide for practitioners
21.
go back to reference Lasinski BB, Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, Green JM, Stewart BR, Cormier JN, Armer JM (2012) A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. Phys Med Rehabil 4:580–601 Lasinski BB, Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, Green JM, Stewart BR, Cormier JN, Armer JM (2012) A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. Phys Med Rehabil 4:580–601
22.
go back to reference Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373(4):317–327CrossRef Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373(4):317–327CrossRef
23.
go back to reference Casley-Smith JR (1995) Alterations of untreated lymphedema and it's grades over time. Lymphology 28(4):174–185PubMed Casley-Smith JR (1995) Alterations of untreated lymphedema and it's grades over time. Lymphology 28(4):174–185PubMed
24.
go back to reference Mehrara BJ, Greene AK (2014) Lymphedema and obesity: is there a link? Plast Reconstr Surg 134(1):154–160CrossRef Mehrara BJ, Greene AK (2014) Lymphedema and obesity: is there a link? Plast Reconstr Surg 134(1):154–160CrossRef
25.
go back to reference Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92:1368–1377CrossRef Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92:1368–1377CrossRef
26.
go back to reference Eyigör S, Cinar E, Caramat I, Unlu BK (2015) Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema. Support Care Cancer 23(9):2705–2710CrossRef Eyigör S, Cinar E, Caramat I, Unlu BK (2015) Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema. Support Care Cancer 23(9):2705–2710CrossRef
27.
go back to reference Vieira RA, da Costa AM, de Souza JL, Coelho RR, de Oliveira CZ, Sarri AJ, Junior RJ, Zucca-Matthes G (2016) Risk factors for arm lymphedema in a cohort of breast cancer patients followed up for 10 years. Breast Care (Basel) 11(1):45–50CrossRef Vieira RA, da Costa AM, de Souza JL, Coelho RR, de Oliveira CZ, Sarri AJ, Junior RJ, Zucca-Matthes G (2016) Risk factors for arm lymphedema in a cohort of breast cancer patients followed up for 10 years. Breast Care (Basel) 11(1):45–50CrossRef
28.
go back to reference Shah C, Wilkinson JB, Baschnagel A, Ghilezan M, Riutta J, Dekhne N, Balaraman S, Mitchell C, Wallace M, Vicini F (2012) Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys 83(4):1095–1100CrossRef Shah C, Wilkinson JB, Baschnagel A, Ghilezan M, Riutta J, Dekhne N, Balaraman S, Mitchell C, Wallace M, Vicini F (2012) Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys 83(4):1095–1100CrossRef
29.
go back to reference Kim M, Kim SW, Lee SU, Lee NK, Jung S-Y, Kim TH, Lee ES, Kang H-S, Shin KH (2013) A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys 86(3):498–503CrossRef Kim M, Kim SW, Lee SU, Lee NK, Jung S-Y, Kim TH, Lee ES, Kang H-S, Shin KH (2013) A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys 86(3):498–503CrossRef
30.
go back to reference Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O’Toole JA, Isakoff SJ, Specht MC (2015) Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 151(2):393–403PubMedPubMedCentral Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O’Toole JA, Isakoff SJ, Specht MC (2015) Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 151(2):393–403PubMedPubMedCentral
31.
go back to reference Brønstad A, Berg A, Reed RK (2004) Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Phys Heart Circ Phys 287(2):H963–H968 Brønstad A, Berg A, Reed RK (2004) Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Phys Heart Circ Phys 287(2):H963–H968
32.
go back to reference Behar A, Pujade-Lauraine E, Maurel A, Brun M, Lagrue G, Feuilhade De Chauvin F, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43(6):653–658CrossRef Behar A, Pujade-Lauraine E, Maurel A, Brun M, Lagrue G, Feuilhade De Chauvin F, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43(6):653–658CrossRef
33.
go back to reference Kissin M, Della Rovere GQ, Easton D, Westbury G (1986) Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73(7):580–584CrossRef Kissin M, Della Rovere GQ, Easton D, Westbury G (1986) Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73(7):580–584CrossRef
34.
go back to reference Lacomba MT, Sánchez MJY, Goñi AZ, Merino DP, del Moral OM, Téllez EC, Mogollón EM (2010) Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. Br Med J 340:b5396CrossRef Lacomba MT, Sánchez MJY, Goñi AZ, Merino DP, del Moral OM, Téllez EC, Mogollón EM (2010) Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. Br Med J 340:b5396CrossRef
Metadata
Title
Risk factors and prediction model for persistent breast-cancer-related lymphedema: a 5-year cohort study
Authors
I-Wen Penn
Yue-Cune Chang
Eric Chuang
Chi-Ming Chen
Chi-Feng Chung
Chia-Yu Kuo
Tien-Yow Chuang
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 3/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4388-6

Other articles of this Issue 3/2019

Supportive Care in Cancer 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine